TD Cowen Reiterates Buy Rating on Elanco Animal Health
TD Cowen maintains its optimistic outlook on Elanco Animal Health with a $32 price target, a 38.05% upside from the current price.
Key Points
- TD Cowen reaffirmed its buy rating for Elanco Animal Health on June 18, 2026, with a target price of $32.
- TD Cowen's $32 price target implies 38.05% upside from Elanco Animal Health Incorporated's ($ELAN) current $23.18 share price.
- Elanco shares are currently trading at $23.39, with a market cap of approximately $11.68 billion and a forward P/E of 19.73.
- Insiders at Elanco, including CEO Jeffrey Simmons, recently acquired shares, reflecting internal confidence in the company's prospects.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
TD Cowen reiterated its buy rating for Elanco Animal Health Incorporated (NYSE:ELAN) on June 18, 2026, maintaining a price target of $32. This follows a series of positive analyst reviews, signaling continued confidence in the company's market position.
Elanco Animal Health Incorporated Stock Down 3.9%
Shares of NYSE:ELAN traded at $23.39. Elanco has a market cap of $11.68 billion, with a forward P/E ratio of 19.73, indicating expectations of future profitability. The stock's beta of 1.696 suggests it is more volatile than the market. Over the past year, Elanco's shares have traded between $13.16 and $27.72, with a 50-day moving average of $22.96 and a 200-day moving average of $22.59.
$ELAN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Elanco reported revenue of $4.89 billion with a growth rate of 14.9%. Despite this growth, the company posted a negative net margin of 4.95% and a return on equity of -3.77%, indicating ongoing challenges in profitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Elanco Animal Health Incorporated
Several insiders, including President and CEO Jeffrey Simmons, EVP and CFO Robert Vanhimbergen, and Rajeev Modi, made recent purchases of Elanco stock. On June 12, 2026, they acquired shares at an average price of $24.17. This buying activity may signal their confidence in Elanco's future prospects.
Analysts Set New Price Targets
On June 18, 2026, TD Cowen maintained its buy rating with a $32 price target. Similarly, Citigroup and JP Morgan maintained buy ratings in May 2026, with targets of $31 and $30, respectively. Currently, 14 analysts have a strong buy recommendation, with a consensus target price of $29.79.
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, headquartered in Indianapolis, Indiana, is a global leader in animal health. The company develops and markets products for pets and farm animals, focusing on parasiticides, vaccines, and therapeutics. Led by CEO Jeffrey N. Simmons, Elanco employs approximately 9,400 people worldwide.
Bottom Line
TD Cowen's reiterated buy rating and $32 target for Elanco Animal Health reflect ongoing confidence in the company's long-term growth potential. Investors often track analyst ratings to gauge market sentiment, and this update suggests optimism about Elanco's future. However, it's important to remember that these ratings are based on past data and market conditions may change.
Get Elanco Animal Health Incorporated alerts
New 13F filings, insider trades, and analyst moves on $ELAN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.